期刊文献+

蛋白酶体抑制剂通过Bcl-2相关抗凋亡蛋白3剪切诱导乳腺癌MCF-7细胞凋亡 被引量:1

Proteasome Inhibitor Induced Apoptosis in MCF-7 Breast Cancer Cells Through Cleavage of BAG3 Protein
原文传递
导出
摘要 [目的]探讨蛋白酶体抑制剂诱导乳腺癌MCF-7细胞凋亡与BAG3蛋白剪切的相互关系,以及BAG3蛋白剪切是否依赖胱天蛋白酶介导完成。[方法]选取人MCF-7乳腺癌细胞系,设空白对照组、MG132处理组、Z-VAD处理组和MG132+Z-VAD联合组。实时定量RT-PCR和Western Blot分别检测各组细胞中BAG3 mRNA和蛋白的表达水平;流式细胞仪检测细胞凋亡。[结果]MG132诱导乳腺癌细胞凋亡过程中BAG3基因和蛋白表达均增高(P<0.05),但BAG3蛋白剪切体也随之增加,流式细胞术结果证明细胞凋亡率增高(P<0.05)。同时,应用胱天蛋白酶体抑制剂Z-VAD处理细胞后,BAG3蛋白剪切体消失。[结论]蛋白酶体抑制剂可诱导上调乳腺癌MCF-7细胞中BAG3基因和蛋白的表达,但BAG3蛋白裂解增强,可导致细胞凋亡增加,这一效应可能依赖胱天蛋白酶介导完成。 [Purpose] To investigate the role of BAG3 in proteasome inhibitor mediated apopto- sis in breast cancer MCF-7 cells and whether BAG3 was cleaved in a caspase-dependent man- ner. [Methods] MCF-7 cell was cultured and treated with vehicle,MG132,pancaspase inhibitor Z-VAD or combination of Z-VAD and MG132. BAG3 mRNA and protein levels were analyzed by RT-PCR and Western Blot respectively.Flow cytometry (FCM) was used to determine the apoptotic rate of cells. [ Results ] Western Blot and Real-time PCR showed that both mRNA and protein expressions of BAG3 in the cells increased by MG132 treatment (P〈0.05) and cleavage product of BAG3 was also induced by MG132,accompanied with increasing apoptosis rate (P〈 0.05). Cleavage of BAG3 was inhibited by caspase inhibitor Z-VAD. [Conclusion] Proteasome inhibitor could induce the up-regulation of BAG3 mRNA and protein in MCF-7 cells,but the enhanced proteolytic cleavage of BAG3 could be contribute to increasement of apgptosis,whose process might be mediated in a caspase-dependent manner. Subject words: caspase; Bcl-2-associated athanogene 3 ; proteasome inhibitor; breast neoplasms
机构地区 辽宁省肿瘤医院
出处 《肿瘤学杂志》 CAS 2014年第2期81-85,共5页 Journal of Chinese Oncology
基金 沈阳市科技局科学技术研究项目(P120552)
关键词 胱天蛋白酶 Bcl-2相关抗凋亡基因3 蛋白酶体抑制剂 乳腺肿瘤 caspase Bcl-2-associated athanogene 3 proteasome inhibitor breast neoplasms
  • 相关文献

参考文献16

  • 1Tanaka K,Yoshimura T,Kumatori A,et al. Proteasomes (muhiprotease complexes) as 20S ring-shaped particles in avariety of eukaryotic cells[J]. J Biol Chem, 1988,263(31): 16209-16217.
  • 2Almond JB, Cohen GM. The proteasome:a novel target for cancer chemotherapy[J]. Leukemia,2002,16(4):433-444.
  • 3Doong H,Price J,Kim YS,et al. CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C- gamma and Hsp70/ Hsc70[J]. Oncogene,2000,19(38) : 4385-4395.
  • 4Antoku K,Maser RS,Seully WJ Jr,et al. Isolation of Bcl-2 binding proteins that exhibit homology with BAG21 and suppressor of death domains protein [J]. Biochem Biophys Res Commun,2001,286 (5):1003-1010.
  • 5McCollum AK,Casagrande G,Kohn EC. Caughtinthemid- dle:the role of Bag3 in diseases[J]. Biochem J, 2009,425 (1): 1-3.
  • 6Wang HQ, Liu BQ,Gao YY,et al. Inhibition of the JNK signaling pathway enhances proteasome inhibitor-induced apoptosis of kidney cancer cells by suppression of BAG3 expression [J]. Br J Pharmaeol,2009,158 (5):1405-1412.
  • 7陈浩月,刘澎,孙淼,吴玲玉,朱华渊,乔纯,董华洁,朱丹霞,徐卫,李建勇.Bag3基因在慢性淋巴细胞白血病的表达及其与预后关系的研究[J].中国实验血液学杂志,2010,18(4):838-842. 被引量:4
  • 8Chiappetta G, Ammirante M, Basile A, et al. The anti-apop- totic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor re- lated apoptosis inducing ligand[J]. J Clin Endocrinol Metab, 2007,92(3) : 1159-1163.
  • 9高雁艳,刘宝琴,牛小芳,庄颖,王华芹.胰腺癌细胞凋亡伴随胱天蛋白酶依赖性BAG3蛋白剪切的研究[J].中华肿瘤防治杂志,2011,18(2):81-84. 被引量:6
  • 10张海燕,高雁艳,刘宝琴,邓娓娓,刘国良,王华芹.Bcl-2相关抗凋亡基因3对蛋白酶体抑制剂抗肿瘤作用影响的观察[J].中华肿瘤防治杂志,2009,16(21):1621-1624. 被引量:3

二级参考文献104

  • 1徐卫,李建勇,潘金兰,仇海荣,沈云锋,肖冰,陈丽娟,吴亚芳,盛瑞兰,薛永权.慢性淋巴细胞白血病的分子遗传学特点[J].中华肿瘤杂志,2006,28(5):349-352. 被引量:13
  • 2刘桐宇,叶建新.蛋白酶体抑制剂治疗多药耐药肿瘤机制的研究进展[J].中华肿瘤防治杂志,2007,14(15):1187-1190. 被引量:6
  • 3Tanaka K, Yoshimura T, Kumatori A, et al. Proteasomes ( multiprotease complexes)as 20S ring-shaped particles in a variety of eukaryofic cells [ J ]. J Biol Chem, 1988, 263 ( 31 ) : 16209 - 16217.
  • 4Kisselev AF, Goldberg AL. Proteasome inhibitors:from research tools to drug candidates[J]. Chem Biol, 2001, 8 (8) :739 - 758.
  • 5Yang YL, Kitagaki J, Wang HH, et al. Targeting the ubiquitinproteasome system for cancer therapy [ J ]. Cancer Sci, 2009, 100 (1) :24 -28.
  • 6Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition[ J ]. J Pept Sci, 2009, 15 (2) :58 -66.
  • 7Meiners S, Ludwig A, Stangl V, et al. Proteasome inhibitors: poisons and remedies [ J ]. Med Res Rev, 2008, 28 (2) :309 - 327.
  • 8Koegl M, Hoppe T, Schlenker S, et al. A novel ubiquitination factor, E4, is involved in uhiubiquitin chain assembly [ J ]. Cell, 1999, 96(5) :635 -644.
  • 9Karin M, Cao Y, Greten FR, et al. NF-KB in cancer:from innocent bystander to major culprit[ J]. Nat Rev Cancer, 2002, 2 (4) :301 -310.
  • 10King RW, Deshaies RJ, Peters JM, et al. How proteolysis drives the cell cycle [ J ]. Science, 1996, 274 ( 5293 ) : 1652 - 1659.

共引文献17

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部